Article
Debrisoquin oxidation genotype and susceptibility to lung cancer.
Clinical pharmacology and therapeutics - 1 Jan 1994
Agúndez J A, Martínez C, Ladero J M, Ledesma M C, Ramos J M, Martín R, Rodriguez A, Jara C, Benítez J
Abstract excerpt
The association between the polymorphism of the cytochrome P450 debrisoquin hydroxylase (CYP2D6) and lung cancer is controversial. Previous reports suggested a link between CYP2D6 phenotype and lung cancer, with poor metabolizers having reduced susceptibility. Nevertheless, negative findings have...
Topics
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Bronchogenic
- Cytochrome P-450 CYP2D6
- Cytochrome P-450 Enzyme System
- Disease Susceptibility
- Female
- Genotype
- Heterozygote
- Humans
- Lung Neoplasms
- Male
- Middle Aged
- Mixed Function Oxygenases
- Oxidation-Reduction
- Phenotype
- Polymorphism, Genetic